Study on the mesothelin-specific cytotoxicity against epithelial ovarian cancer with full-length mesothelin cDNA-transduced dendritic cells

Medical Oncology
Dong-hui WangHai-Rong Yao

Abstract

Epithelial ovarian cancer (EOC) has the highest mortality rate among the various types of gynecological cancers. As the current therapeutic approaches are not enough, the development of more effective treatments to improve the survival of patients with EOC is urgently needed. Mesothelin (MSLN) is a cell surface glycoprotein, which is overexpressed in ovarian cancer tissues. As an immunotherapeutic approach, in this study, we investigated whether the genetically modified dendritic cells (DCs) expressing MSLN could induce cytotoxic T lymphocytes (CTLs) to produce MSLN-specific cytotoxic activity against EOCs. Here, we report that DCs transfected with full-length coding sequence of MSLN could induce MSLN-specific CTLs responses against ovarian cancer lines SKOV3 and OVCAR3 in vitro. Additionally, we identified that the death rates of ovarian cancer cells, killed by MSLN-specific CTLs, were significantly higher than the normal CTLs. Furthermore, IFN-γ production by stimulated MSLN-specific CTLs was significantly higher than that of unstimulated CTLs. This study showed that induced CTLs by DCs with full-length MSLN cDNA have effective immune response against the ovarian cancer cells, indicating that MSLN-transfected DCs vaccine has ...Continue Reading

References

Jan 9, 1996·Proceedings of the National Academy of Sciences of the United States of America·K Chang, I Pastan
Apr 14, 1999·CA: a Cancer Journal for Clinicians·S H LandisP A Wingo
Jul 7, 2000·Seminars in Surgical Oncology·C H Holschneider, J S Berek
May 11, 2002·Nature Reviews. Immunology·Drew M Pardoll
Jan 17, 2003·The New England Journal of Medicine·Lin ZhangGeorge Coukos
Dec 17, 2003·The Journal of Biological Chemistry·Armin RumpAtsushi Miyajima
Aug 6, 2005·Applied Immunohistochemistry & Molecular Morphology : AIMM·Raffit HassanMark C Willingham
Sep 8, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Junko YokokawaKwong Y Tsang
Jul 25, 2006·Advances in Cancer Research·Claudia PalenaJames W Hodge
May 4, 2007·The Journal of Clinical Investigation·Eli Gilboa
Jun 22, 2007·Gene Therapy·C-L ChangC-F Hung
Sep 6, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alfonso CristaudoRiccardo Puntoni
Sep 6, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Raffit HassanIra Pastan
Dec 25, 2008·Methods in Molecular Biology·Jennifer Permuth-Wey, Thomas A Sellers
Sep 12, 2009·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Raffit HassanIra Pastan
Apr 16, 2013·Critical Reviews in Immunology·Bridget CharbonneauMelissa S Derycke
Jun 27, 2013·Gynecologic Oncology·John B Liao, Mary L Disis
Jul 11, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Cheryl Lai-Lai ChiangGeorge Coukos
Dec 18, 2013·Immunotherapy·Jean Pierre Spinosa, Darja Kanduc
Feb 7, 2014·Oncoimmunology·An CoosemansStefaan W Van Gool

❮ Previous
Next ❯

Citations

Oct 1, 2020·Journal of Biochemical and Molecular Toxicology·Amoura M Abou-El-NagaRami M Elshazli

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.